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Summary
Purpose:  To  assess  the  prevalence  and  determinants  of  non-adherence  to  antiretro-
viral  therapy  (ART)  as  well  as  the  concordance  of  two  screening  criteria  in  a  major
center  for  human  immunodeﬁciency  virus  (HIV)  treatment  in  Yaounde,  Cameroon.
Methods:  In  2011,  we  conducted  a  cross-sectional  study  involving  a  random  sample
of  889  adults  (age  >  18  years,  67.9%  women)  infected  with  HIV  who  were  receiving
chronic  care  at  the  Yaounde  Jamot  Hospital.  Adherence  was  assessed  via  self-
administered  questionnaires  using  the  Community  Programs  for  Clinical  Research  on
AIDS  (CPCRA)  index  and  the  Center  for  Adherence  Support  Evaluation  (CASE)  index.
Results:  The  prevalence  of  non-adherence  to  ART  was  22.5%  based  on  the  CPCRA
index  and  34.9%  based  on  the  CASE  index,  with  a  low  agreement  between  the  two
indexes  [kappa  =  0.37  (95%  conﬁdence  interval  0.31—0.44)].  Independent  determi-
nants  of  CPCRA-diagnosed  non-adherence  were  as  follows:  being  a  remunerated
employee  [odds  ratio  (95%  conﬁdence  interval):  1.61  (1.14—2.28)],  Pentecostal
Christianity  [2.18  (1.25—3.80)],  alcohol  consumption  [1.65  (1.16—2.34)]  and  non-
adherence  to  cotrimoxazole  prophylaxis  [5.73  (3.92—8.38)].  The  equivalents  for
CASE-diagnosed  non-adherence  were  [1.59  (1.19—2.12)],  [1.83  (1.36—2.47)],  [1.70
(1.27—2.28)],  respectively,  in  addition  to  association  with  changes  to  the  ART  regi-
men  [1.61  (1.17—2.20)].
∗ Corresponding author at: Yaounde Jamot’s Hospital, PO Box 4021-Yaounde, Cameroon. Tel.: +237 9653972; fax: +237 22203165.
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nce  to  ART  remains  high  in  this  population.  The  careful  eval-
e  presence  of  determinants  of  non-adherence  identiﬁed  in
ptimization.
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inhibitor (nevirapine  or  efavirenz).  Second-lineConclusions:  Non-adhere
uation  of  patients  for  th
this  study  may  aid  ART  o
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Introduction
The  advent  of  highly  active  antiretroviral  ther-
apy (HAART)  was  a  major  breakthrough  in  the
global ﬁght  against  human  immunodeﬁciency  virus
(HIV) infection.  The  adoption  of  HAART  is  gradu-
ally changing  the  landscape  of  HIV  infection  from  a
highly fatal  condition  to  a  chronic  disease,  and  peo-
ple on  HAART  live  longer  and  in  relatively  healthy
condition. With  the  improving  access  to  treatment,
patients with  HIV  in  Africa  (68%  of  the  global  popu-
lation  with  HIV  infection)  have  begun  to  enjoy  the
beneﬁts  of  HAART,  although  mortality  from  HIV  is
still unacceptably  high.  Indeed,  the  estimated  1.2
million Africans  who  died  of  HIV-related  illnesses
in 2010  represent  69%  of  the  global  1.8  million
deaths attributable  to  the  epidemic  in  that  year
[1].  Access  to  care  for  HIV  infection  in  Africa  is  still
fraught with  many  challenges,  including  poor  orga-
nization  of  healthcare  infrastructures,  inadequate
funding and  limited  human  capacity  [2,3].  The  con-
sequences  of  these  challenges,  in  the  form  of  a
discontinuous  drug  supply,  default  from  HAART  or
non-adherence,  are  deterring  factors  to  the  effec-
tiveness  of  antiretroviral  treatment  (ART)  in  this
setting [4].
In  sub-Saharan  African  countries  where  the
HAART scale-up  has  been  successful,  adherence
has been  identiﬁed  as  a  major  challenge  and  an
essential  factor  for  achieving  optimal  HIV  treat-
ment  outcomes.  Adherence  to  HAART  relates  to  the
capacity  of  a  patient  to  take  the  correct  dose  of
each anti-HIV  medication  at  the  correct  time  and
exactly as  prescribed.  It has  been  estimated  that
an adherence  rate  of  at  least  95%  is  needed  to
achieve the  full  effectiveness  of  HAART  treatments
while minimizing  virologic  failure  and  resistance
to ART  [5].  A  meta-analysis  of  27  studies  from  13
African countries  found  that  77%  of  patients  on
ART achieved  an  adequate  level  of  adherence  to
such treatments  [6].  This  analysis,  however,  was
based on  pooling  studies  of  small  size  and  that  were
largely  representative  of  the  era  prior  to  the  more
organized  and  subsidized  treatment  of  HIV  across
Africa.  Reasons  for  poor  adherence  to  ART  likely
vary globally,  with  some  reasons  being  speciﬁc
to the  African  setting  [7,8].  In  Africa,  patient-
level factors  include  limited  purchasing  power  (to
r
c
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icquire  the  medications)  and  remoteness  from
he treatment  centers  [3,4]. However,  community
mpowerment implemented  over  the  last  decade  is
ossibly attenuating  the  impact  of  socio-economic
actors on  the  adherence  to  ART  [9]. Furthermore,
he criteria  for  diagnosing  non-adherence  may  vary
ubstantially  within  a single  population  [10].
Free access  to  ART  was  introduced  in  Cameroon
n May  2007  [11], but  we  are  not  aware  of  any
tudy that  has  investigated  the  issues  involving
dherence in  the  context  of  widespread  access  to
RT in  this  country.  Thus,  the  aims  of  the  present
tudy were  to  determine  the  prevalence  of  non-
dherence  to  ART  and  to  correlate  its  determinants
mong people  infected  with  HIV  in  the  capital  city
f Cameroon  (Yaounde).  We  also  aimed  to  assess  the
oncordance  between  two  common  instruments  for
iagnosing non-adherence.
aterials and methods
tudy settings and participants
his  study  was  conducted  at  the  approved  treat-
ent center  (ATC)  for  HIV  infection  of  the  Yaounde
amot Hospital  (YJH),  which  has  been  described  in
etail elsewhere  [12,13]. Brieﬂy,  YJH  is  the  referral
enter  for  respiratory  diseases  and  tuberculosis  for
he capital  city  of  Cameroon  (Yaounde)  and  the  sur-
ounding areas.  This  hospital  also  hosts  one  of  the
ajor ATCs  in  the  country,  and  as  of  June  2011,  2250
atients  were  receiving  chronic  care  for  HIV  infec-
ion at  the  center.  Patients  treated  for  HIV  infection
re systematically  seen  once  a month  for  drug  pre-
cription  renewal.  Approximately  80—120  patients
reated for  HIV  are  seen  daily.  ART  regimens  in
his center  are  based  on  the  recommendations  of
he Cameroon  National  AIDS  Control  Committee
CNAC) [14].  First-line  ART  regimens  combine  two
ucleosidic  reverse  transcriptase  inhibitors  (zidovu-
ine and  lamivudine  or  emtricitabine  and  tenofovir)egimens combine  two  nucleosidic  reverse  trans-
riptase  inhibitors  not  used  in  the  ﬁrst-line
egimen (zidovudine  and  lamivudine  or  emtric-
tabine and  tenofovir)  with  a  boosted  protease
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non-adherence  to  antiretroviral  therapy  
nhibitor  (ritonavir-boosted  lopinavir).  Second-line
egimens  are  applied  to  patients  (1)  with  HIV-1
nfection who  failed  to  respond  to  a  ﬁrst-line  reg-
men, (2)  with  group  O  HIV-1  infection  or  (3)  with
IV-2  infection.  Patients  aged  18  years  and  above,
n ART  and  who  attended  routine  clinic  visits  during
he recruitment  period  were  considered  for  inclu-
ion in  the  study.
rocedures
his was  a  cross-sectional  study  lasting  six  weeks
etween  October  and  November  2011.  A  systematic
andom sampling  was  applied  based  on  a  sampling
nterval  of  two.  The  ﬁrst  patient  (P1)  received
n each  consultation  day  during  the  recruitment
eriod was  included.  Thereafter,  all  patients  of  the
rder P1  +  2  ×  N  (N  being  a  natural  number  between
 and  60)  were  invited  to  take  part  in  the  study.
atient inclusion  took  place  each  day  through  to
he last  registered  patient  for  that  day.  Patients
ere contacted  for  the  study  via  nurses  and  physi-
ians involved  in  routine  patient  follow-up  at  the
TC. Consenting  patients  were  directed  to  one  of
he six  specially  trained  investigators.  Procedures
or completing  the  self-administered  questionnaire
ere individually  explained  to  each  participant.
nxiety was  assessed  using  the  Generalized  Anxi-
ty Disorder  7-item  (GAD-7)  questionnaire  [15], and
epression  was  assessed  using  the  Patient  Health
uestionnaire-9  (PHQ-9)  [16]. Self-reported  adher-
nce to  cotrimoxazole  prophylaxis  was  based  on
he estimated  percentage  of  tablets  taken  during
he last  seven  days,  with  less  than  90%  of  tablets
aken considered  to  be  poor  adherence.  Additional
ata collection  included  socio-demographic  details
age, sex,  education,  occupation  and  residence),
ehavioral characteristics  (use  of  condoms,  alco-
ol consumption,  smoking  habits,  illicit  drug  use,
amily support  for  adherence,  personal  history  of
tigmatization  and  use  of  native  drugs  and  food
upplements)  and  clinical  and  therapeutic  data
diagnosed  duration  of  HIV  infection,  duration  on
RT, active  opportunistic  infection  and  particularly
uberculosis, severity  of  immune  depression  prior
o starting  ART,  most  recent  CD4  count,  ART  regi-
ens and  changes  in  such  regimens).  The  primary
easons for  skipping  medication  were  also  inves-
igated  by  asking  participants  to  choose  from  a
ist of  possible  reasons,  including  side  effects  of
edications,  number  of  tablets  to  take,  forget-
ulness, being  away  from  home,  eating  difﬁculties
equired for  taking  drugs,  privacy  concerns  or drug
onfusion.  The  study  was  approved  by  the  Ethics
ommittee of  the  Faculty  of  Medicine  and  Biomedi-
al Sciences  of  the  Yaounde  1  University,  Cameroon,
S
D
s309
nd  signed  informed  consent  was  obtained  from  all
articipants.
ssessment  of  the  adherence  to  antiretroviral
herapy
wo instruments  were  used  to  assess  adherence
o antiretroviral  drugs:  (1)  the  Antiretroviral  Med-
cation Self-Report  7-day  recall  self-administered
uestionnaire,  developed  by  the  Community  Pro-
rams for  Clinical  Research  on  AIDS  (CPCRA)  [17],
nd (2)  the  Adherence  index  of  the  Center  for
dherence support  Evaluation  (CASE  adherence
ndex) [18].
The  CPCRA  self-report  comprises  5  items  indicat-
ng the  level  of  adherence  to  each  of  the  prescribed
edications over  the  last  7  days.  Participants  were
sked to  choose  a unique  answer  from  the  follow-
ng options:  ‘During  the  past  7 days  prior  to  this
isit, I  took  all  my  tablets,  I took  them  most  of  the
ime, I  took  them  about  half  of  the  time,  I  took
hem less  often  or  I  took  none  of  my  tablets.’  These
nswers  correspond  to  adherence  rates  of  100%,
0%, 50%,  20%  and  0%,  respectively.  A  CPCRA  score
95% based  on  the  average  of  sub-scores  from  each
f the  prescribed  medications  was  used  to  indicate
oor adherence  [19].
The CASE  adherence  index  is  a composite  score
omprising three  self-report  adherence  items.  The
rst item  (A1)  assesses  difﬁculties  in  taking  med-
cations  on  time  (score  of  1—4),  the  second  item
A2) assesses  the  mean  number  of  days  during
hich the  patients  missed  at  least  one  dose  of
edications (score  of  1—6),  and  the  third  item
A3) assesses  the  last  time  the  patient  missed  at
east one  dose  of  medication  (score  of 1—6).  The
ASE  index  score  is  determined  by  the  formula
ASE index  = A1  +  A2  +  A3.  A  score  >  10  indicates
ood adherence,  and  a score  ≤  10  indicates  poor
dherence  [18].
ata  available
 total  of  932  patients  were  seen  at  the  ATC  of  the
aounde  Jamot  Hospital  during  the  study  period.
orty-three (4.6%)  of  these  patients  were  excluded
ue  to  lack  of  consent  (16  patients),  inappropriate
ompletion of  the  self-reported  questionnaires  (17
atients) or  non-conversance  with  either  English  or
rench languages  (10  patients).  Demographic  and
linical proﬁles  of  the  excluded  participants  were
imilar to  those  of  the  included  participants  (data
ot shown).tatistical methods
ata  were  analyzed  with  the  use  of  SPSS® v.17
tatistical software  for  Windows® (SPSS  Inc.,
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Chicago,  IL).  Quantitative  variables  were  expressed
as mean  and  standard  deviation  (SD)  or  median
and 25—75th  percentiles,  and  qualitative  variables
were  expressed  as  count  and  percentages.  The
comparison  of  the  groups  was  conducted  with
the Pearson’s  2 test  or  Fisher’s  exact  test  for
qualitative variables  and  Student’s  t-test  or  non-
parametric  equivalents  for  quantitative  variables.
The agreement  between  instruments  for  diagnos-
ing non-adherence  was  assessed  via  Spearman’s
correlations  and  kappa  statistics.  Logistic  regres-
sion models  were  used  to  investigate  the  potential
determinants of  non-adherence  to  ART.  Candidate
variables selected  for  testing  in  ﬁnal  multivari-
able models  were  based  on  a  p-value  <  0.10.  A
p-value <  0.05  was  used  to  characterize  statistically
signiﬁcant results.
Results
Study population
The  proﬁles  of  the  889  patients  (604  [67.9%]
women) included  are  shown  in  Table  1. The  median
age (25—75th  percentiles)  was  40  (34—48)  years,
182 (20.5%)  had  primary  level  education  or  less,  427
(48%) had  remunerated  employment,  37  (4.2%)  had
active tuberculosis,  99  (11.1%)  had  anxiety  disor-
ders, 864  (97.2)  were  on  ﬁrst-line  ART  and  231  (26%)
had been  on  ART  for  more  than  4 years.
Prevalence of and reasons for
non-adherence to ART
Non-adherence  to  ART  was  found  in  200  patients
[22.5% (95%  conﬁdence  interval:  19.8—25.2%)]
based on  CPCRA  index  and  in  310  patients  [34.9%
(31.7—38)]  using  the  CASE  index.  Spearman’s  cor-
relation  coefﬁcient  between  the  two  indexes  on  a
continuous  scale  was  0.40  (p  <  0.001).  Among  non-
adherent  patients  identiﬁed  by  the  CPCRA  index
(n =  200),  the  CASE  index  conﬁrmed  the  diagnosis
in 139  (69.5%)  and  reclassiﬁed  61  others  (30.5%)
as adherent.  Among  the  689  patients  classiﬁed  as
adherents  by  the  CPCRA  index,  the  CASE  index  con-
ﬁrmed the  diagnosis  in  518  (75.2%)  and  reclassiﬁed
171 others  (24.8%)  as  non-adherent.  The  CPCRA
index conﬁrmed  the  diagnosis  in  139  (44.8%)  of
the 310  classiﬁed  as  non-adherent  based  on  CASE
index  and  reclassiﬁed  61  (10.5%)  as  non-adherent
out of  the  579  classiﬁed  as  adherent  by  the  CASE
index. The  agreement  between  the  two  indexes  was
below average  [kappa  =  0.37  (95%  conﬁdence  inter-
val: 0.31—0.44)].  The  prevalence  of  non-adherence
r
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ased  on  either  of  the  two  indexes  was  41.7%
38.8—45.0%), n  =  371.
Reasons for  non-adherence  among  the  371  non-
dherent  patients  based  on  either  of  the  indexes
re depicted  in  Fig.  1. The  main  reasons  were  as
ollows: forgetting  to  take  the  ART  (40.4%),  being
way  from  home  at  the  time  ART  must  be  taken
38.3%) and  concerns  about  privacy  (14.6%).
eterminants of non-adherence to ART
he  determinants  of  non-adherence  are  shown
n Tables  2 and  3  separately  for  each  of  the
ndexes. In  univariable  analyses  (Table  2),  using  a
-value < 0.10,  remunerated  employment,  educa-
ion, religious  afﬁliation  (CPCRA  index  only),  use
f condoms  (CPCRA  index  only),  alcohol  consump-
ion, past  history  of  tuberculosis  (CASE  index  only),
urrent ART  regimen  (CASE  index  only),  change  of
he ART  regimen,  duration  on  ART  and  adherence
o cotrimoxazole  prophylaxis  were  associated  with
on-adherence.
In multivariable  models,  mutually  adjusted  for
igniﬁcant  predictors  in  univariable  analyses,  hav-
ng a remunerated  employment  [odds  ratio  1.61
95% conﬁdence  interval:  1.14—2.28)  based  on
PCRA index  and  1.59  (1.19—2.12)  based  on  CASE
ndex], alcohol  consumption  [1.65  (1.16—2.34)
nd 1.83  (1.36—2.47)]  and  non-adherence  to
otrimoxazole  prophylaxis  [5.73  (3.92—8.38)  and
.70 (1.27—2.28)]  were  signiﬁcant  predictors  of
on-adherence  to  ART  for  both  indexes.  Fur-
hermore, being  a  Pentecostal  Christian  [1.65
1.16—2.34)] was  associated  with  CPCRA-based
on-adherence,  and  a change  in  the  ART  regimen
1.61 (91.17—2.20)]  was  associated  with  CASE-
ased non-adherence  (Table  3).
iscussion
his  large  cross-sectional  study  conducted  in  a
ajor ATC  for  HIV  infection  in  a urban  set-
ing in  sub-Saharan  Africa  indicates  that  (1)
t least  one  quarter  of  HIV  patients  receiv-
ng ART  are  non-adherent  to  such  treatments
ased on  self-reported  7-day  recall;  (2)  the  two
elf-administered  questionnaires  used  to  diagnose
on-adherence  had  a  poor  agreement  in  this  popu-
ation, which  may  have  major  implications  on  the
ecommendation  for  routine  clinical  practice;  (3)
emunerated  employment,  alcohol  consumption,
on-adherence  to  cotrimoxazole  prophylaxis  and  to
 certain  extent  Pentecostal  religion  and  change
n ART  regimens  were  the  main  determinants  of
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Table  1  Socio-demographic,  clinical  and  therapeutic  characteristics  of  patients  with  HIV  on  antiretroviral
treatment.
Characteristics  Categories  n  =  889  (%)
Sex  Women  604  (67.9)
Age,  years <30  86  (9.7)
30—59  776  (87.3)
≥60 27  (3.0)
Median  (25—75th  percentiles) 40  (34—48)
Urban  residence Urban  727  (81.8)
Education No  schooling 32  (3.6)
Primary  school  150  (16.9)
Secondary  school  537  (60.4)
University  or  equivalents  170  (19.1)
Occupation Remunerated  427  (48)
None/housewife  462  (52)
Living  in  couple  Yes  391/882  (44.3)
Condom  use
Past  history  of  tuberculosis
Never  473  (53.2)
Sometime  202  (22.7)
Never  214  (24.1)
Yes  353  (39.7)
Active  tuberculosis Yes  37  (4.2)
Smoking  Yes  21  (2.4)
Alcohol  consumption Yes 311  (35)
Anxiety Present  99  (11.1)
Absent  790  (88.9)
Depression Present 190  (21.4)
Absent  699  (78.6)
Pre  ART  CD4  count,  per  mm3 Median  (25—75th  percentiles) 122  (57—183)
Current  CD4  count,  per  mm3 Median  (25—75th  percentiles) 342  (235—481)
Current  ART  regimens 1st  line 864 (97.2)
2nd  line 25 (2.8)
Duration  on  ART,  years <1 216  (24.3)
1—4  442  (49.7)
>4  231  (26)
Median  (25—75th  percentiles)  2.5  (1—4.2)
CPCRA  adherence  index  to  ART Adherent  689  (77.5)
Non-adherent  200  (22.5)
CASE  adherence  index  to  ART Adherent  579(65.1)
Non-adherent  310(34.9)
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iART: antiretroviral therapy; CPCRA: Self-Report 7-day recall 
(CPCRA); CASE: Center for Adherence Support Evaluation
on-adherence;  and  (4)  forgetting,  being  away  from
ome at  the  time  the  ART  is  to  be  taken  and  need
f privacy  were  the  main  reasons  for  non-adherence
isclosed by  patients.
The  CASE  index  [18]  assesses  adherence  over
 period  of  several  weeks  prior  to  the  consul-
ation and  in  our  study  has  provided  prevalence
ates similar  to  those  found  by  Boyer  et  al.  [4]  in
ameroon,  who  used  a  questionnaire  that  assessed
dherence  to  ART  over  the  four  weeks  before
he consultation.  The  study  by  Boyer  [4]  included
ore ART-treated  participants  (2381)  from  27  treat-
ent centers  across  the  country  but  was  based  on
ata collected  prior  to  the  implementation  of  the
ree access  to  ART  in  the  country  [11]. That
f
a
s
lloped by Community Programs for Clinical Research on AIDS
he  prevalence  of  non-adherence  in  our  study  is
imilar to  that  reported  by  Boyer  et  al.  [4]  sug-
ests that  decreasing  the  cost  of  acquiring  ARTs
as not  improved  adherence  in  the  urban  setting  of
he country.  Indeed,  the  cost  of  medications  is  just
ne component  of  the  overall  cost  of  caring  for  HIV
nfection,  and  patients  in  this  setting  are  still  con-
ronted with  other  ﬁnancial  charges,  including  the
osts of  transportation,  laboratory  tests  and  treat-
ents for  opportunistic  conditions  related  to  HIV
nfection [11]. The  prevalence  of  non-adherence
ound in  our  study  was  also  within  the  sampling  vari-
tion of  the  pooled  estimates  from  meta-analysis  of
tudies on  adherence  to  ART  in  Africa  in  the  era  of
imited  access  to  such  treatments  [6,20].
312
 
E.W
.
 Pefura-Yone
 et
 al.
Table  2  Characteristics  associated  to  adherence  of  antiretroviral  therapy,  by  self-report  type.
Characteristics  CPCRA  adherence  index  CASE  adherence  index
Non-adherent  (n  =  200) Adherent  (n  =  689) p-Value Non-adherent  (n  =  310)  Adherent  (n  =  579)  p-Value
Female,  n  (%) 133  (65.5) 471  (68.4) 0.620 202  (65.2)  402  (69.4)  0.194
Median  age,  years  (IQR) 39  (34—45)  40  (34—49)  0.110  39  (34—46.25)  40  (34—49)  0.313
Urban  residence,  n  (%)  158  (79.0)  569  (82.6)  0.248  251  (81.0)  476  (82.2)  0.647
University  education,  n  (%)  47  (23.5)  123  (17.9)  0.074  69  (22.3)  101  (17.4)  0.082
Living  in  couple,  n  (%)  87  (43.5)  304  (44.6)  0.788  140  (45.2)  251  (43.9)  0.715
Having  an  employment,  n  (%)  111  (55.5)  316  (45.9)  0.016  169  (54.5)  258  (44.6)  0.005
Religious  afﬁliation  0.051  0.196
Catholic  Christian,  n  (%)  127  (64.1)  418  (61.4)  194  (63.4)  351  (61.3)
Protestant  Christian,  n  (%)  35  (17.7)  156  (22.9)  56  (18.3)  135  (23.6)
Pentecostal  Christian,  n  (%)  26  (13.1)  51  (7.5)  34  (11.1)  43  (7.5)
Muslim,  n  (%) 6  (3.0) 30  (4.4) 11  (3.6) 25  (4.4)
Others,  n  (%) 4 (2.0) 26  (3.0) 11  (3.6) 19  (3.3)
Duration  of  transportation  <  45  mina,  n  (%) 93  (46.5) 283  (41.1) 128  (41.3) 248  (42.8) 0.657
Use  of  the  condoms 0.061 0.147
Always,  n  (%) 97  (48.5) 376  (54.6) 159  (51.3) 314  (54.2)
Sometimes,  n  (%)  58  (29.0)  144  (20.9)  82  (26.5)  120  (20.7)
Never,  n  (%) 45 (22.5)  169  (24.5)  69  (22.3)  145  (25.0)
Regular  food,  n  (%)  170  (85.0)  584  (84.8)  264  (85.2)  490  (84.6)
Alcohol  consumption,  n  (%)  93  (46.5)  218  (31.6)  <0.001  141  (45.5)  170  (29.4)  <0.001
Smoking,  n  (%)  4  (2.0)  17  (2.5)  >0.999  7  (2.3)  14  (2.4)  0.881
Pas  history  of  TB,  n  (%)  82  (41.2)  271  (39.4)  0.645  136  (44.0)  217  (37.5)  0.061
Active  TB,  n  (%)  7  (3.5)  30  (4.4)  0.594  12  (3.9)  25  (4.3)  0.751
BMI  <  18.5  kg/m2 at  ART  start,  n  (%)  35  (17.5)  100  (14.5)  0.300  48  (15.5)  87  (15.0)  0.856
CD4  count  at  ART  start,  n  (%)  0.473  0.596
>  200/mm3,  n  (%)  36/194  (18.6)  143/677  (21.1)  58/307  (18.9)  121/564  (21.5)
50—200/mm3,  n  (%)  119/194  (61.3)  381/677  (56.4)  183/307  (59.6)  318/564  (56.4)
<  50/mm3,  n  (%)  39/194  (20.1)  152/677  (22.5)  66/307  (21.5)  125/564  (22.2)
Anxiety,  n  (%)  24  (12.0)  75  (10.9)  0.659  34  (11.0)  65  (11.2)  0.907
Mental  depression,  n  (%)  45  (22.5)  145  (21.0)  0.659  66  (21.3)  124  (21.4)  0.985
Actual  ART  regimen,  n  (%)  0.504  0.068
First  line,  n  (%)  193  (96.5)  671  (97.4)  297  (95.8)  567  (97.9)
Second  line,  n  (%)  7  (3.5)  18  (2.6)  13  (4.2)  12  (2.1)
Change  of  ART  protocol,  n  (%)  143  (71.5)  439(63.7)  0.042  223  (71.9)  359  (62.0)  0.003
ART  duration  <  1  year,  n  (%) 38  (19.0) 178  (25.8) 0.047 58 (18.7) 158  (27.3) 0.004
Traditional  treatment  for  HIV,  n  (%) 11  (5.5) 23  (3.3) 0.161 14  (4.5) 20  (3.5)  0.431
Good  adherence  to  cotrimoxazole  prophylaxis,  n  (%) 43/196  (21.9) 412/662  (62.2)  <0.001  132/303  (43.6)  323/555  (58.2)  <0.001
CPCRA (Self-Report 7-day recall adherence), Community Programs for Clinical Research on AIDS; CASE: Center for Adherence Support Evaluation.
a Between patient house and Yaounde Jamot Hospital.
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Figure  1  Reasons  for  non-adherence  to  antiretroviral  therapy  in  Yaounde,  Cameroon.
Table  3  Multivariable  adjusted  odds  ratio  and  95%  conﬁdence  intervals  for  predictors  of  antiretroviral  non-
adherence.
Risk  factors  CPCRA  adherence  index  CASE  adherence  index
AOR  (95%  CI)  p-Value  AOR  (95%  CI)  p-Value
Age  <  50  years  /  /  1.14  (0.77—1.70)  0.493
University  level  of  education  1.30  (0.85—2.00)  0.229  1.18  (0.81—1.70)  0.386
Having  an  employment  1.59  (1.11—2.26)  0.011  1.51  (1.13—2.04)  0.006
Pentecostal  Christianity  2.11  (1.20—3.72)  0.010  1.54  (0.93—2.57)  0.095
Use  of  condoms  at  times  1.03  (0.66—1.61)  0.885  1.22  (0.79—1.89)  0.377
Alcohol  consumption  1.51  (1.05—2.16)  0.025  1.78  (1.31—2.41)  <0.001
Past  history  of  tuberculosis  /  /  1.28  (0.95—1.72)  0.106
Having  switched  ART  regimen  1.31  (0.85—2.03)  0.226  1.45  (1.00—2.10)  0.049
Treatment  duration  ≥  1  year  1.28  (0.79—2.11)  0.328  1.21  (0.80—1.85)  0.361
Poor  adherence  to  cotrimoxazole  5.83  (3.97—8.56)  <0.001  1.70  (1.26—2.28)  0.001
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Recent  studies  based  on  composite  scores  such
s the  CASE  index  have  found  prevalences  of non-
dherence  that  were  much  lower  than  that  of
ur study  in  African  countries  such  as  Ethiopia
24.3%) and  Kenya  (18%)  [21,22]. Suggestions  have
een made  that  such  scores  were  more  reliable
han questionnaires  that  attempt  to  assess  non-
dherence  by  only  investigating  missed  doses  of
edications  [18]. This  discrepancy  may  explain
ome of  the  disagreement  between  the  CASE  and
PCRA  indexes  in  our  study.  Indeed,  we  found  a low
greement  between  the  two  indexes.  This  situation
ay have  undesirable  consequences,  particularly
hen patients  who  are  in  need  of  more  assistance  to
mprove adherence  to  medications  are  misclassiﬁed
s
p
t for Clinical Research on AIDS; CASE; Center for Adherence
erapy.
s  adherent  by  a given  diagnostic  instrument.  Poor
greement  between  different  self-reported  adher-
nce measures  has  been  described  previously  in
he literature  [23,24].  The  large  number  of  these
ndexes  used  to  measure  adherence  makes  it  difﬁ-
ult to  compare  the  results  of  studies  on  adherence,
ncluding the  results  among  studies  based  on  self-
eports.  It  has  been  suggested  that  the  use  of
ifferent  instruments  may  result  not  only  in  a  dif-
erence  in  prevalence  but  also  in  the  range  of
redictors of  non-adherence  across  studies  and
ettings  [25].
The  reasons  for  non-adherence  disclosed  by
articipants in  our  study  were  largely  similar  to
hose reported  in  other  studies  from  Africa  [21,26].
n
t
a
c
[
i
p
T
c
t
s
u
a
g
n
w
t
a
i
o
A
e
[
t
a
C
F
R314  
However,  three  factors  emerged  as  the  most  dom-
inant,  accounting  for  approximately  93%  of  the
reasons  disclosed  by  participants  (i.e.,  forgetting,
being away  from  home  at  the  time  ART  medications
are to  be  taken  and  privacy  concerns).  Exploring
these leading  factors  in  non-adherent  patients  may
aid personalized  counseling  and  the  personalization
of treatment  plans.
Three  of  the  ﬁve  determinants  identiﬁed  in  our
study were  common  to  non-adherence  diagnosed
in both  of  the  two  indexes,  whereas  two  deter-
minants were  speciﬁc  to  each  of  the  indexes.  The
association  of  remunerated  employment  with  non-
adherence  found  in  our  study  contrasts  with  reports
from  existing  studies  [4,6,22].  Disclosed  reasons  for
non-adherence  were  largely  similar  between  remu-
nerated  workers  and  non-workers  (data  not  shown),
which  makes  speculation  on  the  observed  associ-
ation difﬁcult.  However,  the  association  between
alcohol consumption  and  non-adherence  found  in
our study  is  in  agreement  with  ﬁndings  from  two
recent  meta-analyses  [6,27].  Similarly,  a  previous
study in  Cameroon  also  found  a  change  of  ART
regimen to  be  associated  with  non-adherence  [4].
These consistent  ﬁndings  highlight  the  importance
of patients’  past  experience  on  adherence  as  well
as the  complexity  of  daily  coping  with  ART  [4].
Preaching  healing  messages  against  HIV  infection
through faith  is  not  uncommon  in  some  religious
groups in  the  study  setting  [28]. Such  messages
may negatively  impact  adherence  and  help  explain
the association  of  non-adherence  with  Pentecostal
Christianity in  our  study.  The  observed  association
between non-adherence  to  ART  and  non-adherence
to cotrimoxazole  would  tend  to  suggest  that  non-
adherence  to  ART  reﬂects  a  generalized  attitude
toward chronic  medications  in  general  and  not
speciﬁcally  to  ART.  Other  determinants  of  non-
adherence  reported  elsewhere,  including  young  age
[29],  remoteness  from  the  treatment  center  [22],
anxiety [30],  depression  [27]  and  difﬁculties  eating
regularly  [4],  were  not  conﬁrmed  in  our  study.
Limitations  of  the  current  study  include  its
cross-sectional nature,  which  precluded  reliable
assessment  of  the  direction  of  the  observed  asso-
ciations.  The  indirect  assessment  of  adherence
using self-administered  questionnaires  is  subject  to
recall bias,  may  not  be  appropriate  for  individuals
with memory  disorders  and  tends  to  overestimate
adherence relative  to  more  objective  methods  such
as pill  count  and  automated  pharmacy  databases
[10,31].  Other  methods,  such  as  the  use  of  elec-
tronic data  banks  [32]  or  prescription  data  [33], are
also more  objective  methods,  but  their  implemen-
tation and  use  in  countries  with  limited  resources
must be  evaluated.  In  addition,  drug  provision  doesE.W.  Pefura-Yone  et  al.
ot  automatically  imply  that  patients  will  take
he drugs  as  prescribed.  However,  the  use  of  self-
dministered  questionnaires  is  cheap,  speciﬁc  and
onvenient for  use  in  busy  routine  clinical  practice
10,17—19]. A  major  advantage  of  the  current  study
s the  large  sample  size  as  compared  with  many
revious studies  on  adherence  to  ART  in  Africa  [6].
his large  sample  size  has  increased  the  statisti-
al power  and  enabled  a careful  examination  of
he potential  risk  factors  of  non-adherence  in  this
etting.
In conclusion,  non-adherence  to  ART  is  still
nacceptably high  in  this  population,  even  years
fter the  implementation  of  a  free  access  pro-
ram to  ART.  Different  instruments  for  diagnosing
on-adherence identify  different  groups  of  patients
ithin the  same  population.  Ultimately,  however,
he presence  of  factors  that  are  found  to  be  associ-
ted with  non-adherence,  irrespective  of  diagnostic
nstruments,  should  prompt  careful  investigation
f any  underlying  lower-than-optimal  adherence  to
RT and  other  prescribed  chronic  medications.  Sev-
ral interventions  for  improving  adherence  exist
34], some  of  which  can  easily  be  implemented  in
he study  setting  to  maximize  the  outcomes  of  ART
mong people  living  with  HIV  infection.
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